Published on The Nathan Kline Institute for Psychiatric Research (https://www.nki.rfmh.org)

Home > A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population

A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population [1]

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Length: 
Approximately 4 months
Disorder/Condition: 
Autism
Inclusion Criteria: 

Males and Females, ages 13-17 with ASD and presence of irritability and GI symptoms

Study Title (brief): 
A Three-arm, Parallel Group, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in a 13- to 17-year-old Autism Spectrum Disorder Population
Study Description (brief): 

The primary objective of this study is to evaluate the effectiveness and safety of an investigational medication compared with placebo in improving irritability symptoms in individuals with ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org [2]

Study Location: 
Nathan Kline Institute, Orangeburg, NY

Source URL:https://www.nki.rfmh.org/content/three-arm-parallel-group-randomized-double-blind-placebo-controlled-study-efficacy-safety

Links
[1] https://www.nki.rfmh.org/content/three-arm-parallel-group-randomized-double-blind-placebo-controlled-study-efficacy-safety [2] mailto:vrp@nki.rfmh.org